Semaglutide and Epigenetic Aging: Evidence That GLP-1 Receptor Agonists May Slow Biological Age
Key takeaway: A randomized controlled trial suggests that semaglutide, a GLP-1 receptor agonist, significantly slows epigenetic aging in people with HIV-associated lipohypertrophy, supporting the hypothesis that GLP-1 peptides may improve biological age and cellular healthspan, not just weight loss or glycemic control. Key takeaway: A randomized controlled trial suggests that semaglutide, a GLP-1 receptor agonist, significantly slows […]